Table 1. Optimization of Reaction Conditionsa
entry
[Rh] catalyst
ligand
Ph[B] (equiv)
additive (equiv)
solvent
dioxane
temp (°C)
yieldb (%)
1
2
3
4
5
6
7
8
9
10
[Rh(acac)(coe)2]
[Rh(MeCN)2(cod)]BF4
[RhOH(cod)]2
[RhCl(cod)]2
dppbenz
À
PhB(OH)2 (2.0)
PhB(OH)2 (2.0)
PhBF3K (2.0)
PhB(OH)2 (2.0)
PhB(OH)2 (2.0)
(PhBO)3 (1.5)
(PhBO)3 (1.5)
(PhBO)3 (1.5)
(PhBO)3 (1.5)
(PhBO)3 (1.5)
Et3N (2.0)
70
rt
60
80
rt
rt
rt
rt
rt
rt
37c
10d
0d
Et3N (2.0)
1:2 dioxane/H2O
2:3 DMF/H2O
H2O
dppbenz
SSPhos
SSPhos
SSPhos
À
Et3N (2.0)
NaOH (1.2)
NaOEt (1.2)
NaOEt (1.2)
NaOEt (1.2)
NaOEt (1.2)
NaOEt (1.2)
NaOEt (1.2)
0d
[RhCl(cod)]2
EtOH
29e
70e
71e
84f
0
[RhCl(cod)]2
EtOH
[RhCl(cod)]2
EtOH
[RhCl(cod)]2
À
4:1 dioxane/EtOH
dioxane
[RhCl(cod)]2
À
[RhCl(cod)]2
dppbenz
4:1 dioxane/EtOH
quant
a General reaction conditions: 4 mol % of rhodium and 4 mol % of ligand were used. The reaction time was 18 h. b Yields were determined by
1H NMR of the crude material relative to 1,3,5-trimethoxybenzene as an external standard. c 9% of imine 1 remained. d Imine 1 was completely con-
sumed. e Ethoxy addition byproduct was observed in 20À30% yield. f Ethoxy addition product was observed in <5% yield.
derived aldimines,4c and trifluoroacetaldimines.4d How-
ever, to date the Rh-catalyzed addition of organoboron
reagents to N-sulfinyl ketimines has not been reported.6
We report here the highly functional group compatible
Rh-catalyzed addition of readily available arylboroxines to
activated N-tert-butanesulfinyl ketimines to provide 3-amino-
oxetanes,7,8 3-aminoazetidines,9 and 3-aminooxindole10
tertiary carbinamines. Notably, each of these pharmacophores
has seen recent and extensive use in drug candidates.7,10
We began our investigation by exploring a variety of
reaction conditions for phenyl boron reagent addition to
imine 1, which is activated by both ring strain and the
electronegative ring oxygen (Table 1). Under our pre-
viously developed reaction conditions for additions to
N-sulfinyl aldimines,4a a 37% yield of the desired product
2a was obtained (entry 1). Reported aqueous reaction
conditions4b,5,11 for organoboron reagent addition re-
sulted in complete consumption of imine 1, but little if
any desired product was observed (entries 2À4). However,
when the base and solvent were changed to NaOEt and
EtOH, respectively, a 29% yield of 2a was obtained even at
room temperature (entry 5). Because hydrolysis of 1 was
problematic, in order to exclude water, we next evaluated
arylboroxines, which are conveniently obtained by drying
commercially available arylboronic acids. Indeed, when
phenylboroxine was used, a considerable increase in pro-
ductyield was observed (entry 6). Significantly, the catalyst
in the absence ofthe sulfonatedS-Phosligandhadidentical
reactivity (entry 7), suggesting that this bulky monoden-
tate ligand was not participating in the active catalyst.
When EtOH was used as the sole solvent an ethoxy-
addition byproduct was formed in 20À30% yield (entries
5À7). This side reaction was minimized by using 20%
EtOH in dioxane (entry 8). In contrast, no reaction
occurred in the absence of EtOH (entry 9). Notably, addi-
tion of 1,2-bis(diphenylphosphino)benzene (dppbenz) to
air stable [RhCl(cod)]2 provided the product in quantita-
tive yield (entry 10).
(4) (a) Weix, D. J.; Shi, Y.; Ellman, J. A. J. Am. Chem. Soc. 2005, 127,
1092. (b) Bolshan, Y.; Batey, R. A. Org. Lett. 2005, 7, 1481. (c) Beenen,
M. A.; Weix, D. J.; Ellman, J. A. J. Am. Chem. Soc. 2006, 128, 6304.
(d) Truong, V. L.; Pfeiffer, J. Y. Tetrahedron Lett. 2009, 50, 1633.
(5) (a) Brak, K.; Ellman, J. A. J. Am. Chem. Soc. 2009, 131, 3850.
(b) Brak, K.; Ellman, J. A. J. Org. Chem. 2010, 75, 3147.
(6) Hayashi and co-workershave recently published on the first example
of Rh-catalyzed additions of organoboron reagents to ketimines with the
enantioselective catalytic addition of sodium tetraarylborates and potassium
aryltrifluoroborates to N-sulfonyl aromatic ketimines using chiral diene
ligands. (a) Shintani, R.; Takeda, M.; Tsuji, T.; Hayashi, T. J. Am. Chem.
Soc. 2010, 132, 13168. (b) Shintani, R.; Takeda, M.; Soh, Y.-T.; Ito, T.;
Hayashi, T. Org. Lett. 2011, 13, 2977.
(7) For recent reviews on the high level of utility of oxetanes in drug
discovery, including 3-amino derivatives, see: (a) Wuitschik, G.; Carreira,
E. M.;Wagner, B.; Fischer, H.; Parrilla, I.; Schuler, F.;Rogers-Evans, M.;
€
Muller, K. J. Med. Chem. 2010, 53, 3227. (b) Burkhard, J. A.; Wuitschik,
€
G.; Rogers-Evans, M.; Muller, K.; Carreira, E. M. Angew. Chem., Int. Ed.
2010, 49, 9052.
(8) For the preparation of 3-aminooxetanes by the addition of a
variety of organolithium reagents to N-sulfinyl imine 1 prepared from
oxetan-3-one, see ref 3g.
To establish the reaction scope, a variety of arylborox-
ines was explored (Scheme 1). Electron-rich arylboroxines
with para-andmeta-substituents were well tolerated (2bÀ2e).
However, the ortho-methylphenylboroxine resulted in a
poor conversion even at 60 °C (2f), presumably due to
ꢀ
(9) (a) Burkhard, J. A.; Guerot, C.; Knust, H.; Rogers-Evans, M.;
Carreira, E. M. Org. Lett. 2010, 12, 1944. (b) Burkhard, J. A.; Wagner,
€
B.; Fischer, H.; Schuler, F.; Muller, K.; Carreira, E. M. Angew. Chem.,
Int. Ed. 2010, 49, 3524.
(10) For examples of drug candidates containing the 3-aminooxo-
indole pharmacophore, see: (a) Decaux, G.; Soupart, A.; Vassart, G.
Lancet 2008, 371, 1624. (b) Shimazaki, T.; Iijima, M.; Chaki, S. Eur. J.
Pharmacol. 2006, 543, 63. (c) Ochi, M.; Kawasaki, K.; Kataoka, H.;
Uchio, Y.; Nishi, H. Biochem. Biophys. Res. Commun. 2001, 283, 1118.
(11) White, J. R.; Price, G. J.; Plucinski, P. K.; Frost, C. G. Tetra-
hedron Lett. 2009, 50, 7365.
Org. Lett., Vol. 13, No. 15, 2011
3913